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Purpose: To report that iopamidol myelography can induce status epilepticus (SE) in patients carrying the diagnosis of symp-
tomatic epilepsy and to estimate the incidence of seizures in patients undergoing iopamidol myelography.
Methods: We retrospectively identified all patients with seizures/SE associated with 1350 iopamidol myelographies during the
last 5 years at our institution. The impact of cervical versus lumbar myelography was analysed.
Results: Induced by iopamidol myelography two non-epileptic patients suffered from first generalised tonic-clonic seizures and
a 67-year-old women with symptomatic epilepsy after a remote ischemic stroke developed a generalised tonic-clonic seizure
evolving into a dialeptic and right nystagmus SE (i.e. complex focal status) of 5-hour duration. The incidence of seizures in
non-epileptic patients was 0.15%. The incidence of seizure induction for lumbar myelography was lower than for myelographies
that included the cervical subarachnoid space.
Conclusions: Iopamidol myelography (especially if cervical) is associated with a risk of seizures in non-epileptic individuals
and can induce SE in patients with epilepsy. Patients should be informed about the risk of seizure induction.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Iopamidol is a nonionic iodinated contrast medium
commonly used in myelography. Although epileptic
seizures are less frequently induced by iopamidol
myelography than by myelography with metriza-
mide, they are a known complication of iopamidol
and should not be underestimated1–8. Epilepsy is a
restriction for the use of iopamidol. To the best of
our knowledge status epilepticus (SE) has never been
described except for one seizure series possibly rep-
resenting SE1. Here we present a case of SE induced
by iopamidol myelography and give an incidence
estimate for seizures induced by iopamidol myelo-
graphy.
CASE REPORTS
A 67-year-old women developed a symptomatic fo-
cal epilepsy after an ischemic infarction in the left
precentral area 5 years ago. She suffered from rare
right-sided clonic seizures. The antiepileptic ther-
apy consisted of clobazam 10 mg per day, phenytoin
200 mg per day and levetiracetam 2000 mg per day.
She underwent run-up myelography of the cervical
spine for compression of the right C6 nerve root
caused by a suspected disk prolapse between the
cervical vertebrae five and six. At our institution the
standard dose consists of 10.2 g iopamidol which was
injected at the lumbar level. The patient was posi-
tioned head downwards to allow the contrast medium
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Fig. 1: EEG during and after iopamidol myelography-induced SE: (a) EEG 25 minutes after the onset of SE: EEG-status,
lateralised left maximum temporal; (b) EEG 2 hours after onset of SE: EEG-status, generalised maximum left (periodic
lateralised epileptiform discharges); (c) EEG 18 hours after termination of the status. (1) Sharp-wave, regional left temporal;
(2) continuous slow, lateralised left; (3) background slowing.
to float from the lumbar to the cervical subarachnoid
space. Forty-five minutes after the injection of iopami-
dol the patient had a generalised tonic-clonic seizure
which progressed to a complex-partial status with
nystagmus to the right (semiological classification9:
SE: generalised tonic-clonic seizure → dialeptic
status and right nystagmus status). It was her first
episode of SE ever. Fig. 1a displays the electroen-
cephalogram (EEG) 25 minutes after the onset of the
status and Fig. 1b shows the EEG 120 minutes after
the onset of the status. It was not possible to stop the
status with 3 mg lorazepam intravenously. Only when
additional 5 mg lorazepam and 1200 mg phenytoin
were given intravenously the SE was controlled after
5 hours. Additional doses of phenytoin were intra-
venously administered leading to a phenytoin level of
31.2 mg l−1, 5 hours after termination of the status.
The EEG 18 hours after termination of the status is
presented in Fig. 1c. Three hours after the onset of
the status, a computed tomography of the head was
performed. Iopamidol was present in the vicinity of
the infarction (Fig. 2). Other causes for the develop-
ment of the status could not be identified. The patient
recovered with no sequels and was transferred to
neurosurgery for therapy of the disk prolapse.
In the 5-year period between July 1997 and June
2002 we observed two other patients who devel-
oped an epileptic seizure induced by iopamidol
myelography. Both patients had no known epilepsy.
The first was a 35-year-old male who had a gen-
eralised tonic-clonic seizure several hours after a
lumbar iopamidol myelography. The second was a
40-year-old female who had a cervical myelography
because of a stenosis of the spinal canal. During
the myelography the patient developed a generalised
tonic-clonic seizure. Postictally she was confused for
about 36 hours with initial fever.
Between July 1997 and June 2002, 1350 myelogra-
phies with iopamidol were carried out. Therefore, the
incidence of epileptic seizures induced by iopamidol
myelography in patients without epilepsy was 0.15%
(2/1350). As 80.1% of our myelographies were lum-
bar and only 19.9% included a cervical myelography
the incidence of seizure induction for lumbar myel-
ography was lower (0.09%) as compared to cervical
myelography (0.37%).
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Fig. 2: Computed tomography of the head 3.5 hours after cervical myelography: hyperdense iopamidol is seen in the vicinity of
the remote ischemic stroke in the left precentral area.
DISCUSSION
Seizure induction in epileptic patients
This report of a SE induced by iopamidol myelography
and one reported seizure series possibly representing
SE1 support the restricted use of this contrast medium
in epileptic patients. Two additional patients with
known epilepsy reported by Levey et al.4 developed
seizures induced by lumbar iopamidol myelogra-
phy. Therefore, in patients with epilepsy the gain of
information by a iopamidol myelography must be
Table 1: Seizures induced by iopamidol myelography in non-epileptic patients.
Reference Number of all Cases of seizures Incidence
patients (lumbar/cervical) (%)
This study 1350 2 (1/1) 0.15
Carchietti et al.1 – 1 (1/0) –
Carella et al.2 – 1 (0/1) –
Grunert and Pendl3 1070 1 (1/0) 0.093
Levey et al.4 785 1 (0/1) 0.127
Lipman et al.5 236 2 (1/1) 0.847
Olsen6 – 1 (1/0) –
Sobel et al.7 152 1 (?) 0.658
Teasdale and Macpherson8 300 (cervical) 2 (0/2) 0.667
For all publications total number of patients, cases of seizures and incidence of seizures were given (if available).
weighed against the risk of inducing seizures or SE.
The patient should be informed about the risk of
seizure induction.
Seizure induction in non-epileptic patients
In our retrospective series the incidence for seizures
induced by iopamidol myelography in non-epileptic
patients was 0.15% which is in the range of 0–0.847%
described in the literature (Table 1)3–5, 7, 8, 10. Addi-
tional patients with seizures induced by iopamidol
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myelography have been reported without incidence
estimates1, 2, 6. The seizures typically develop within
12 hours after injection of the contrast medium6. Inter-
estingly, two non-epileptic patients developed seizures
induced by cervical myelography despite antiepileptic
prophylaxis with phenytoin5 or sodium valproate8.
Cervical versus lumbar myelography
We found a higher incidence of seizure induction
for cervical as compared to lumbar myelography.
Including our two cases, 55% (6/11) of the reported
seizures were induced by cervical myelography al-
though this type of myelography comprises not more
than one-third of all myelographies in most centres
including ours7, 11. Therefore, cervical myelographies
may have a higher risk of seizure induction. The high-
est incidence of seizure induction by iopamidol was
reported in studies investigating patients undergoing
cervical myelographies only8 or including seizures
induced by cervical iopamidol myelography5. It has
already been reported for iopamidol that side effects
were more frequent in cervical as compared to lum-
bar myelographies11. Furthermore, it has been shown
for metrizamide that EEG effects are more prominent
with cervical than with lumbar myelographies12.
These findings may be related to the different tech-
niques used in cervical and lumbar myelography. Dur-
ing a cervical myelography the contrast medium is
injected into the lumbar subarachnoid space and af-
terwards the patient is positioned head downwards so
that the contrast medium floats from the lumbar to the
cervical and in part to the cranial subarachnoid space.
Alternatively, iopamidol is directly injected into the
cervical subarachnoid space.
Once the contrast medium has reached the cranial
subarachnoid space, it enters the extracellular space
by passive diffusion through the pia mater. There it
causes changes in the transmitter metabolism which
may result in overexcitability of the neurons3.
In lumbar myelography the contrast medium is in-
jected into the lumbar subarachnoid space and no
run-up technique is used so that most of the contrast
medium remains in the lumbar subarachnoid space
where it cannot irritate the cortex.
Alternative contrast media and
protective medications
It is well established that metrizamide has a higher risk
of seizure induction than iopamidol. However, there
is not much information about the risk of seizures in-
duced by other nonionic contrast media. The results
of comparative bioessays are often conflicting13, 14. In
one bioassay the neural tolerance of iodixanol for ex-
ample has been considered to be at least equal to that
of iopamidol13. In a different bioessay the acute neuro-
toxicity of iopamidol has been considered to be lower
than that of iodixanol14. No cases of epileptic seizures
induced by iodixanol myelography were reported ei-
ther in the literature or to the producer (Amersham
Buchler GmbH & Co., Germany). However, iodixanol
is only approved for myelography in several countries
and has been used less frequently for this indication.
For the time being we recommend to use iopami-
dol for myelography because its risk of seizure induc-
tion is known and low. Nevertheless informed consent
should include the risk of seizure induction and ben-
zodiazepines should be at hand.
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